| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:23590819 | IVTH | 0.0005 M | 0.0005 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0005 M | 0.0005 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00025 M | 0.00025 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00025 M | 0.00025 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.001 M | 0.001 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.001 M | 0.001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:23670170 | IVTH | 0.00001 M | 0.00001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0001 M | 0.0001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:24298046 | IVR | 350 mg/kg/day | 350 mg/kg/day | Nipple retention | Reproductive endocrine-mediated perturbations |
| IVR | 350 mg/kg/day | 350 mg/kg/day | Decreased weights of bulbocavernosus muscles/LABC | Reproductive endocrine-mediated perturbations | |
| PMID:26259604 | IVR | 50 mg/kg | 50 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/kg | 50 mg/kg | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| PMID:29665328 | IVTH | 0.00000137 M | 0.00000137 M | Affects survival of germ cells | Reproductive endocrine-mediated perturbations |
| IVR | 350 mg/kg/day | 350 mg/kg/day | Affects germ cell development in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:31305161 | IVR | 400 mg/kg | 400 mg/kg | Oxidative stress in nervous system | Neurological endocrine-mediated perturbations |
| IVR | 400 mg/kg | 400 mg/kg | Decreased serotonin (5-HT) levels | Neurological endocrine-mediated perturbations | |
| IVR | 400 mg/kg | 400 mg/kg | Decreased noradrenaline levels | Neurological endocrine-mediated perturbations | |
| IVR | 400 mg/kg | 400 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 400 mg/kg | 400 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 400 mg/kg | 400 mg/kg | Decreased dopamine levels | Neurological endocrine-mediated perturbations | |
| IVR | 400 mg/kg | 400 mg/kg | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 400 mg/kg | 400 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 400 mg/kg | 400 mg/kg | Decrease in Thyrotropin-releasing hormone (TRH) levels | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.